TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
TQ-B3525 tablet is a new α/δ dual inhibitor phosphatidylinositol 3-kinase inhibitor developed
by Chia Tai Tianqing pharmaceutical Group Co., Ltd. It can overcome the drug resistance
problem caused by the up-regulation of phosphatidylinositol 3-kinase α subunit activity
caused by the single inhibition of phosphatidylinositol 3-kinase δ subunit. This study is a
single-arm, open-label, multi-cohort, multi-center clinical study of the safety and efficacy
of TQ-B3525 tablets combined with osimertinib in subjects with advanced non-small cell lung
cancer, aiming to evaluate TQ-B3525 tablets combined with osimertinib, the safety,
tolerability, and efficacy of the treatment of patients with advanced non-small cell lung
cancer who have failed epidermal growth factor receptor inhibitor therapy, while exploring
the efficacy, resistance mechanism, and safety in the dose escalation phase biomarkers.